FT819 in Subjects With B-cell Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Bendamustine
Related studies linked through entity extraction aliases.
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
- Status
- COMPLETED
- Phase
- PHASE3
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
- Status
- TERMINATED
- Phase
- PHASE3
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Status
- RECRUITING
- Phase
- PHASE1
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
- Status
- WITHDRAWN
- Phase
- PHASE2
Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)
- Status
- UNKNOWN
- Phase
- N/A
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
FT516 in Subjects With Advanced Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Compassionate Use Re-Infusion of ATLCAR.CD30
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A